Efficacy and safety of Duloxetine compared with placebo for diabetic neuropathy pain: meta-analysis.
Loading...
Date
2016-07
Journal Title
Journal ISSN
Volume Title
Publisher
Abstract
Background: Duloxetine is relatively considered as a treatment for
diabetic neuropathy pain due it is balanced and potent reuptake
inhibitor of both serotonin and nor epinephrine where these
neurotransmitters play a great in pain inhibition.
Materials and Methods: We searched DLX related articles in
Pubmed, Cochrane and Embase from 2005 to 2010. 158 articles
were found after through search out of which 68 articles were case
reports, reviews and meta-analysis, 40 studies were clinical trials
but not efficient data was available, 45 studies were RCTs but not
related to our topic. Only 5 RCTs included after exclusion. We then
performed the meta-analysis of the studies which met our eligibility
criteria we performed fixed effect model network meta-analysis to
analyze the efficacy of DLX compare to placebo. We chose diabetic
neuropathy duration, diabetes mellitus duration, types of diabetes
and DLX with regard to MNSI scale.
Results: 5 published RCTs were included in this meta-analysis no
significant difference observed for DLX and DND [(SD mean
difference 0.22 (95%CI -0.16 to 0.60); P=0.25)] , on diabetes mellitus
duration for HbA1c and fasting blood glucose (FBG) [(SD mean
difference -0.00 (95%CI-0.087 to 0.87); P=1.00)] and on types of
diabetes[(COR 1.00 (95% CI 0.73 to 1.38; P=0.98)] and [(OR 1.00 (95%
CI 0.72 to 1.37); P=0.98)] .DLX shown to have significant efficacious
compared to placebo for MNSI (95% CI -0.37 to – 0.03); P=0.02)].
Conclusion: In the fixed effect model analyses of DLX, showed
similar efficacy to placebo for efficacy parameters, except on MNSI
scale but not clinically relevant.
Description
Keywords
Duloxetine, serotonin (5-HT), nor-epinephrine, diabetic neuropathy, diabetes mellitus, MNSI, Meta-analysis
Citation
Hassan M A, Cheng X Y, Dai Z, Rahmathullah M N, Shahnawaz, Shamsa H, Fathuma H, Hussein A H. Efficacy and safety of Duloxetine compared with placebo for diabetic neuropathy pain: meta-analysis. International Journal of Medical and Dental Sciences. 2016 July; 5(2): 1304-1311.